No registrations found.
ID
Source
Brief title
Health condition
primary HIV-1 infection
HIV-1 evolution
viral fitness
Human Leukocyte antigen (HLA)
Sponsors and support
Investigator driven study, no industrial study
Investigator driven study, no industrial study
Intervention
Outcome measures
Primary outcome
1. Sequence of the viral genome that is present in the HIV-1 donor as close as possible to the time of HIV-1 transmission;
2. Virus diversity in the donor-recipient pairs half a year after HIV-1 transmission;
3. HLA type of donor-recipient pairs, availability of replication competent (pseudo)viruses from donor and recipient.
Secondary outcome
The relation between viral sequence dynamics and:
1. The HLA type of donor and recipient;
2. The autologous neutralization profile;
3. Host CTL responses;
4. Viral fitness.
Background summary
It is known that HIV-1 variants escape cellular and humarol immunity in the host. This may however have an impact on viral fitness and as a consequence, escape mutations will revert in the face of declining immunity or upon transmission to a new host. The aim of this study is to examine the dynamics of escape mutations and reversions in relation to the HLA type of the HIV-1 donor and the HLA type of the HIV-1 recipient. In addition, the same HIV-1 sequence dynamics in relation to the specificity of the humoral immune response in HIV-1 donor-recipient pairs will be studied.
Study objective
The aim of this study is to examine the dynamics of escape mutations and reversions in relation to the Human Leukocyte antigen (HLA) type of the HIV-1 donor and the HLA type of the HIV-1 recipient. In addition, the HIV-1 sequence dynamics in relation to the specificity of the humoral immune response in HIV donor-recipient pairs will be studied. Since the donor most likely has an established immune response mounted against HIV-1 whilst the recipient does not, it may be expected that different viruses will propagate and different cell types will become infected. Hence, the virus in both donor and recipient pairs will be investigated as close as possible to the time of transmission. Simultaneously, the cellular compartments in which HIV resides and replicates will be analyzed.
Study design
1. Screening;
2. Visit 1: baseline;
3. Visit 2: 24 wks after baseline.
Intervention
Venapuncture done twice with 128 ml blood extraction each time.
F4- 217,
P.O. Box 22660
J.M. Prins
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5664380
j.m.prins@amc.uva.nl
F4- 217,
P.O. Box 22660
J.M. Prins
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5664380
j.m.prins@amc.uva.nl
Inclusion criteria
1. HIV-1 infected partners who are assumed to be the source of HIV-1 transmission (donor) of patients who present with primary HIV-1 infection at the ‘Primo-SHM’ study (recipient) in the AMC;
2. At least 18 years of age.
Exclusion criteria
N/A
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1554 |
| NTR-old | NTR1632 |
| Other | MEC AMC : 09/007 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |